S Brady, J Poulton, S Muller - Autoimmunity Reviews, 2024 - Elsevier
Inclusion body myositis (IBM) is a late onset sporadic myopathy with a characteristic clinical presentation, but as yet unknown aetiology or effective treatment. Typical clinical features …
M Benatar, T Hansen, D Rom, MA Geist… - The Lancet …, 2024 - thelancet.com
Background Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 …
S Salam, J Allen, MM Dimachkie… - Clinical and …, 2024 - discovery.ucl.ac.uk
Sporadic inclusion body myositis (IBM) is a progressive condition which commonly affects patients aged above 40. IBM does not respond to immunosuppression and no proven …
O Benveniste - Revue Neurologique, 2024 - Elsevier
The discovery, over the last forty years or so, of specific myositis auto-antibodies (easily dosed in routine nowadays) and the fine clinically and pathologically phenotypic …
Muscle diseases cover a diverse group of disorders that, in most cases, are hereditary. The rarity of the individual muscle diseases provides a challenge for researchers when wanting …
NC Anderson, TE Lloyd - Current Opinion in Rheumatology, 2025 - journals.lww.com
Current Opinion in Rheumatology Log in or Register Subscribe to journalSubscribe Get new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …
Since the publication of the 2013 European Neuromuscular Center (ENMC) diagnostic criteria for Inclusion Body Myositis (IBM), several advances have been made regarding IBM …
Background: Sporadic inclusion body myositis (sIBM) is the predominant idiopathic inflammatory myopathy (IIM) in older people. Limitations of classical clinical assessments …
NA Allameen, S Salam, V Reddy, PM Machado - Rheumatology, 2024 - academic.oup.com
Inclusion body myositis (IBM) remains an enigmatic and complex muscle disorder where a deeper understanding of disease pathomechanisms and the identification of potential …